TL;DR
This study reveals that NAD+ (specifically via Nicotinamide Riboside, NR) can reverse neurological deficits in tauopathy models by modulating alternative RNA splicing (ASEs), particularly affecting the EVA1-C gene. This work highlights ASEs as a key mechanism through which NAD+ exerts its beneficial effects and suggests novel therapeutic avenues for Alzheimer's Disease (AD).
What Problem Does This Paper Address?
Alzheimer's Disease (AD) is a devastating neurodegenerative disorder with limited effective treatments. While NAD+ and its precursors show promise in slowing AD progression, the underlying molecular mechanisms, especially concerning RNA splicing, remain unclear. Aberrant alternative splicing (ASEs) is increasingly recognized as an aging hallmark and a contributor to AD pathology. This paper aims to bridge this gap by investigating how NAD+ influences ASEs in tauopathy models and how these changes impact disease progression, with a specific focus on the EVA1-C gene.
Methods
The researchers employed a multi-faceted approach:
- Transcriptomic Analysis: RNA-sequencing (RNA-seq) was performed on mouse brains (hTau.P301S transgenic mice and wild-type controls) and C. elegans models, both with and without NR treatment, to identify differentially expressed genes and ASEs.
- AI-based Prediction: Deep learning algorithms were used to predict EVA1-C protein structures and protein-protein interactions (PPIs). This included leveraging a novel "PromptProtein" model for enhanced prediction accuracy.
- Experimental Validation: Findings from transcriptomic and AI analyses were validated using various experimental models:
- Cell Culture: Human neuroblastoma SH-SY5Y cells overexpressing tau were used to study EVA1-C protein levels and interactions.
- C. elegans Models: Transgenic worms expressing tauopathy-like pathology were used to assess the impact of NR and EVA1-C knockdown on memory and lifespan.
- Mouse Models: hTau.P301S mice were used to study the effects of NR on behavior and gene expression.
- Post-mortem Human Brain Tissue: Hippocampal and entorhinal cortex samples from AD patients at different Braak stages were analyzed for EVA1-C expression.
- Protein Docking and Molecular Dynamics: Simulations were conducted to estimate binding modes and energetics between EVA1-C isoforms and potential interacting partners like HSP70 and BAG-1.
Datasets
- Mouse RNA-seq Data: Hippocampal RNA-seq data from 14-month-old wild-type (WT) and hTau.P301S mice, treated with or without Nicotinamide Riboside (NR), were utilized.
- C. elegans RNA-seq Data: Data from C. elegans models were used to study aging and tau pathology effects on RNA splicing.
- Human Brain Tissue Data: Post-mortem hippocampal and entorhinal cortex samples from AD patients and age-matched healthy controls were analyzed.
- Public Databases: The STRING database and the AlphaFold Protein Structure Database were used for AI model training and protein structure prediction.
Key Insights and Ideas
- NAD+ as a Splicing Modulator: The study strongly suggests that NAD+ (via NR) isn't just a metabolic booster but actively influences RNA splicing, particularly in the context of neurodegenerative diseases. This opens up a new dimension to understanding NAD+'s therapeutic potential.
- EVA1-C as a Key Player: The EVA1-C gene and its isoforms emerge as a critical target. Its expression is dysregulated in tauopathy and AD, and its modulation by NR appears central to the observed neurological benefits.
- ASEs as a Disease Hallmark: The research reinforces the idea that aberrant alternative splicing is not just a consequence but potentially a driver of tauopathy and AD, making it a promising therapeutic target.
- AI for PPI Prediction: The application of advanced AI models (like PromptProtein) for predicting protein-protein interactions, especially considering 3D structures, represents a significant step forward in understanding complex molecular mechanisms.
Key Results
- NR Reverses Neurological Deficits: NR treatment improved memory and extended lifespan in tauopathic C. elegans models, and these benefits were abrogated when EVA1-C was knocked down, highlighting EVA1-C's crucial role.
- EVA1-C Downregulation in AD: EVA1-C protein levels were significantly reduced in neurons of AD patients across different Braak stages, particularly in the entorhinal cortex and hippocampus.
- NR Modulates EVA1-C Splicing: In tauopathic mice, NR treatment led to differential expression and splicing of EVA1-C isoforms, with some isoforms showing higher affinity for HSP70.
- Widespread ASE Dysregulation: Transcriptomic analysis revealed significant dysregulation of various ASE subtypes (MES, IR, ES) in tauopathic models, with NR treatment showing a normalizing effect.
- AI Predicts Key Interactions: AI-driven PPI prediction identified HSP70 and BAG-1 as likely interaction partners for EVA1-C, with subsequent experimental validation supporting these findings.
Limitations and Future Work
- EVA1-C Isoform-Specific Antibodies: The authors acknowledge the lack of EVA1-C isoform-specific antibodies, which limited the use of direct immunological approaches for validation. They compensated with AI-based deep learning.
- Bulk RNA-seq Limitations: The use of bulk RNA-seq data means that expression values are averaged across different cell types, potentially masking cell-type-specific effects.
- Further Investigation of PPIs: While AI and docking simulations identified potential interactions between EVA1-C, HSP70, and BAG-1, further experimental verification of these specific isoform-protein interactions is warranted.
- Therapeutic Development: The study suggests that developing splice-switching therapeutics targeting NAD+-regulated ASEs, particularly those involving EVA1-C, could be a promising avenue for AD treatment. Future work could focus on optimizing these strategies.
Summary updated